Kendra K. Bence

Kendra K. Bence

Auto-generated profile, based on publicly available information

Kendra K. Bence

Internal Medicine Research Unit, Pfizer Worldwide Research, Development, and Medical, Cambridge, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2002 in Developmental Cell
Verified
Journal Article
Closed access
JZJanice M. Zabolotny
Janice M. Zabolotny
KBKendra K. Bence-Hanulec
Kendra K. Bence-Hanulec
ASAlain Stricker-Krongrad
Alain Stricker-Krongrad
FHFawaz Haj
Fawaz Haj
YWYongping Wang
Yongping Wang
BNBenjamin G. Neel
Benjamin G. Neel

16 July 2006 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
KBKendra K Bence
Kendra K Bence
MDMirela Delibegovic
Mirela Delibegovic
BXBingzhong Xue
Bingzhong Xue
CGCem Z Gorgun
Cem Z Gorgun
GHGokhan S Hotamisligil
Gokhan S Hotamisligil
BKBarbara B Kahn
Barbara B Kahn

1 January 2015 in Cell
Verified
Journal Article
Closed access
GDGarron T. Dodd
Garron T. Dodd
SDStephanie Decherf
Stephanie Decherf
KLKim Loh
Kim Loh
SSStephanie E. Simonds
Stephanie E. Simonds
FWFlorian Wiede
Florian Wiede
TTTony Tiganis
Tony Tiganis

1 March 2009 in Diabetes
Verified
Journal Article
Open access
MDMirela Delibegovic
Mirela Delibegovic
DZDerek Zimmer
Derek Zimmer
CKCaitlin Kauffman
Caitlin Kauffman
KRKimberly Rak
Kimberly Rak
EHEun-Gyoung Hong
Eun-Gyoung Hong
KBKendra K. Bence
Kendra K. Bence
OBJECTIVE—The protein tyrosine phosphatase PTP1B is a negative regulator of insulin signaling; consequently, mice deficient in PTP1B are hypersensitive to insulin. Because PTP1B−/− mice have diminished fat stores, the extent to which PTP1B directly regulates glucose homeostasis is unclear. Previously, we showed that brain-specific PTP1B−/− mice are protected against high-fat diet–induced obesity and glucose intolerance, whereas muscle-specific PTP1B−/− mice have increased insulin sensitivity independent of changes in adiposity. Here we studied the role of liver PTP1B in glucose homeostasis and lipid metabolism. RESEARCH DESIGN AND METHODS—We analyzed body mass/adiposity, insulin sensitivity, glucose tolerance, and lipid metabolism in liver-specific PTP1B−/− and PTP1Bfl/fl control mice, fed a chow or high-fat diet. RESULTS—Compared with normal littermates, liver-specific PTP1B−/− mice exhibit improved glucose homeostasis and lipid profiles, independent of changes in adiposity. Liver-specific PTP1B−/− mice have increased hepatic insulin signaling, decreased expression of gluconeogenic genes PEPCK and G-6-Pase, enhanced insulin-induced suppression of hepatic glucose production, and improved glucose tolerance. Liver-specific PTP1B−/− mice exhibit decreased triglyceride and cholesterol levels and diminished expression of lipogenic genes SREBPs, FAS, and ACC. Liver-specific PTP1B deletion also protects against high-fat diet–induced endoplasmic reticulum stress response in vivo, as evidenced by decreased phosphorylation of p38MAPK, JNK, PERK, and eIF2α and lower expression of the transcription factors C/EBP homologous protein and spliced X box-binding protein 1. CONCLUSIONS—Liver PTP1B plays an important role in glucose and lipid metabolism, independent of alterations in adiposity. Inhibition of PTP1B in peripheral tissues may be useful for the treatment of metabolic syndrome and reduction of cardiovascular risk in addition to diabetes.

1 March 2011 in Cell Metabolism
Verified
Journal Article
Closed access
MHMatthew R. Hayes
Matthew R. Hayes
TLTheresa M. Leichner
Theresa M. Leichner
SZShiru Zhao
Shiru Zhao
GLGrace S. Lee
Grace S. Lee
ACAmy Chowansky
Amy Chowansky
KBKendra K. Bence
Kendra K. Bence

1 August 2021 in Molecular Metabolism
Verified
Journal Article
Open access
KBKendra K. Bence
Kendra K. Bence
MBMorris J. Birnbaum
Morris J. Birnbaum
The incidence of non-alcoholic fatty liver disease (NAFLD) is rapidly increasing worldwide parallel to the global obesity epidemic. NAFLD encompasses a range of liver pathologies and most often originates from metabolically driven accumulation of fat in the liver, or non-alcoholic fatty liver (NAFL). In a subset of NAFL patients, the disease can progress to non-alcoholic steatohepatitis (NASH), which is a more severe form of liver disease characterized by hepatocyte injury, inflammation, and fibrosis. Significant progress has been made over the past decade in our understanding of NASH pathogenesis, but gaps remain in our mechanistic knowledge of the precise metabolic triggers for disease worsening. The transition from NAFL to NASH likely involves a complex constellation of multiple factors intrinsic and extrinsic to the liver. This review focuses on early metabolic events in the establishment of NAFL and initial stages of NASH. We discuss the association of NAFL with obesity as well as the role of adipose tissue in disease progression and highlight early metabolic drivers implicated in the pathological transition from hepatic fat accumulation to steatohepatitis. The close association of NAFL with features of metabolic syndrome highlight plausible mechanistic roles for adipose tissue health and the release of lipotoxic lipids, hepatic de novo lipogenesis (DNL), and disruption of the intestinal barrier in not only the initial establishment of hepatic steatosis, but also in mediating disease progression. Human genetic variants linked to NASH risk to date are heavily biased toward genes involved in the regulation of lipid metabolism, providing compelling support for the hypothesis that NASH is fundamentally a metabolic disease.